Stock AnalizKymera Therapeutics (KYMR) earnings for the quarter ended September 2026: EPS misses estimates
Kymera Therapeutics reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at -$1.32 against the analysts’ average forecast of -$1.27, a miss of 4.3%.
The market’s verdict: the stock rose 0.1% on the first trading day after the report.
The last four quarters
Kymera Therapeutics has beaten the analysts’ EPS forecast in 2 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | -$1.32 | -$1.27 | −4.3% | — | +0.1% |
| Jun 2026 | -$0.62 | -$0.74 | +16.0% | +466% | +1.9% |
| Mar 2026 | -$0.71 | -$0.86 | +17.1% | +55% | −1.0% |
| Dec 2025 | -$0.98 | -$0.77 | −27.1% | −61% | +0.7% |
What comes next
Analysts expect EPS of -$1.29 for the next quarter on average and -$3.93 for the fiscal year ending December 31, 2026.
The average analyst price target is $145.22, 14% above the current price of $127.57.
Valuation and score
Kymera Therapeutics scores 0.6 out of 5 overall on Stock Analiz (weak). Full Kymera Therapeutics analysis with 10 years of financials
Frequently asked questions
What was Kymera Therapeutics’s EPS for the quarter ended September 2026?
-$1.32 adjusted per share, against an analyst consensus of -$1.27.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.